Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 11/20 | 0.61 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | CETP | P11597 | 4/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10021893 | 0.96 | SELP (0.57) | SELPAPPCETPPLA2G4A | |
| SCHEMBL17789071 | 0.93 | SELP (0.54) | SELPAPPCETP | |
| SCHEMBL10021891 | 0.93 | SELP (0.53) | SELPAPPCETP | |
| SCHEMBL10021888 | 0.92 | SELP (0.53) | SELPAPPCETP | |
| SCHEMBL10021889 | 0.92 | SELP (0.55) | SELPAPPCETPPLA2G4A | |
| SCHEMBL10021894 | 0.91 | SELP (0.53) | SELPAPPCETP | |
| SCHEMBL17789069 | 0.91 | SELP (0.51) | SELPAPPCETP | |
| SCHEMBL17789072 | 0.91 | SELP (0.51) | SELPAPPCETP | |
| SCHEMBL17789070 | 0.91 | SELP (0.51) | SELPAPPCETP | |
| SCHEMBL10021896 | 0.89 | SELP (0.51) | SELPAPPCETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151401-A1 | GLYCOLIPIDS AS TREATMENT FOR DISEASE | LA JOLLA PHARMACEUTICAL COMPANY | 2016-06-02 | — | — | US | disclosed |
| US-20120035120-A1 | GLYCOLIPIDS AS TREATMENT FOR DISEASE | SENEB BIOSCIENCES, INC. (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035120-A1 | GLYCOLIPIDS AS TREATMENT FOR DISEASE | GBA2, UGCG, GBA1 | SELP 2417/4885APP 720/4885CETP 571/4885 |
| US-20160151401-A1 | GLYCOLIPIDS AS TREATMENT FOR DISEASE | GBA2, UGCG, GBA1 | SELP 2417/4885APP 720/4885CETP 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.